Growth can hide a lot. In healthcare, it can hide weak contracts, broken denial workflows, underpayment, and documentation problems that make the revenue engine look stronger than it really is. That is why contract-to-cash diligence matters. If you are buying a platform, especially in ABA or pediatric therapy, top-line growth is not enough. You need to know whether the business can turn services into cash without leaking value at every step.
Contract-to-cash diligence is more than an accounting exercise. It is a review of the path from service delivery to payment: authorization, documentation, coding, claims submission, denial management, appeals, payment posting, and underpayment recovery. If any one of those links is weak, reported growth can overstate the quality of the earnings. A business can look healthy in the deck and still be fragile in practice.
That fragility is especially common in provider rollups and fast-growing care platforms. Growth tends to create decentralized workarounds. Teams build local habits. Payer rules vary by market. Documentation discipline slips from location to location. One office knows how to handle a payer exception, another does it differently, and the back office inherits a mess that never appears on the top line.
The warning signs are usually boring, which is why they get missed. Denials cluster by payer but are brushed off as “normal.” Underpayments are not tracked consistently. Contract renewal dates live in someone’s inbox. Authorization exceptions are handled manually and never analyzed. Documentation quality varies enough that the same service line produces very different cash outcomes depending on who is doing the work.
If you are doing diligence, the right questions are practical ones.
Which payers generate the most denials and underpayments? How much revenue depends on manual intervention? Are authorization and reauthorization processes centralized or scattered? Which contracts are expiring soon? How much of the business depends on local knowledge instead of standardized policy? Are billed services consistently supported by the record? What happens to cash if volume grows another 20 percent without adding more administrative headcount?
Those questions matter because not all revenue is equal. Two businesses can report the same EBITDA and still be worth very different amounts depending on how reliable the cash conversion is. One may have clean claims, predictable reimbursement, and tight contract management. The other may need constant intervention to stay afloat. Investors who skip that distinction are not buying growth. They are buying a set of hidden problems with a good forecast.
That is why contract-to-cash diligence should be part of the buy-side process, not a cleanup step after the deal closes. It shows where the margin is real and where it is being held together by habit, heroics, or luck. In a market where healthcare capital is still moving, that distinction matters.
Aegis can support investor diligence with a Revenue Review, a Contract Review, or a Fraud Review if you want a sharper view of cash quality before you buy or scale a platform.